The quarterly results for Yunnan Botanee Bio-Technology Group Co.LTD (SZSE:300957) were released last week, making it a good time to revisit its performance. Revenues came in at CN¥1.2b, in line with estimates, while Yunnan Botanee Bio-Technology GroupLTD reported a statutory loss of CN¥0.16 per share, well short of prior analyst forecasts for a profit. The analysts typically update their forecasts at each earnings report, and we can judge from their estimates whether their view of the company has changed or if there are any new concerns to be aware of. So we collected the latest post-earnings statutory consensus estimates to see what could be in store for next year.

After the latest results, the 21 analysts covering Yunnan Botanee Bio-Technology GroupLTD are now predicting revenues of CN¥7.78b in 2025. If met, this would reflect a substantial 27% improvement in revenue compared to the last 12 months. Statutory earnings per share are predicted to surge 103% to CN¥2.86. Before this earnings report, the analysts had been forecasting revenues of CN¥7.89b and earnings per share (EPS) of CN¥2.93 in 2025. So it looks like there's been a small decline in overall sentiment after the recent results - there's been no major change to revenue estimates, but the analysts did make a small dip in their earnings per share forecasts.

The consensus price target held steady at CN¥63.34, with the analysts seemingly voting that their lower forecast earnings are not expected to lead to a lower stock price in the foreseeable future. The consensus price target is just an average of individual analyst targets, so - it could be handy to see how wide the range of underlying estimates is. There are some variant perceptions on Yunnan Botanee Bio-Technology GroupLTD, with the most bullish analyst valuing it at CN¥109 and the most bearish at CN¥43.00 per share. So we wouldn't be assigning too much credibility to analyst price targets in this case, because there are clearly some widely different views on what kind of performance this business can generate. As a result it might not be a great idea to make decisions based on the consensus price target, which is after all just an average of this wide range of estimates.

These estimates are interesting, but it can be useful to paint some more broad strokes when seeing how forecasts compare, both to the Yunnan Botanee Bio-Technology GroupLTD's past performance and to peers in the same industry. The period to the end of 2025 brings more of the same, according to the analysts, with revenue forecast to display 21% growth on an annualised basis. That is in line with its 21% annual growth over the past five years. Compare this with the broader industry, which analyst estimates (in aggregate) suggest will see revenues grow 16% annually. So it's pretty clear that Yunnan Botanee Bio-Technology GroupLTD is forecast to grow substantially faster than its industry.

The Bottom Line

The most important thing to take away is that the analysts downgraded their earnings per share estimates, showing that there has been a clear decline in sentiment following these results. Fortunately, they also reconfirmed their revenue numbers, suggesting that it's tracking in line with expectations. Additionally, our data suggests that revenue is expected to grow faster than the wider industry. The consensus price target held steady at CN¥63.34, with the latest estimates not enough to have an impact on their price targets.

Following on from that line of thought, we think that the long-term prospects of the business are much more relevant than next year's earnings. We have estimates - from multiple Yunnan Botanee Bio-Technology GroupLTD analysts - going out to 2026, and you can see them free on our platform here.

Before you take the next step you should know about the 4 warning signs for Yunnan Botanee Bio-Technology GroupLTD that we have uncovered.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.